The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q3 2022 call → NOWe need to determine if management conveys that the reported results for the period (Q3 2022) do not represent the business they are actually running today. The call focuses heavily on OASIS trial data, which is a clinical trial for CLS-AX. The reported period is Q3 2022 financials, but the call is dominated by clinical data updates. Management discusses the OASIS trial results, which are not part of the financial results but are the main business activity. They talk about future plans for Phase 2 trial, extension study data, etc. The financial results are briefly mentioned: cash position $53.4 million, runway into 2024. The rest is about clinical progress. The question: does management convey that the reported period (Q3 2022 financials) is stale relative to the operating present? The operating present is the clinical development progress. The financial results are just cash position, which is not the business itself. The business is developing CLS-AX. The call is about the OASIS data, which is a major milestone. Management is presenting data that is new and forward-looking. They are not discussing the financial results as the business. They are discussing the clinical trial results as the main event. The reported period (Q3 2022) includes the financials, but the business is the clinical program. Management is saying that the data from OASIS is very encouraging and they are moving forward. They are not saying that the reported financials are stale; they are just reporting cash. The question is about whether the reported results (financial) do not represent the business actually running today. The business is the clinical development, and the financials are just a snapshot. Management does not dwell on the financials. They focus on the clinical data. However, the question is about the "reported results for the period being discussed" - that is the Q3 2022 earnings. The earnings call includes both financial results and clinical updates. The clinical updates are part of the call but not part of the financial results. The question asks: does management convey that the just-reported numbers (financial) describe a company that has already been left behind by what is now actually happening inside the business? The business is the clinical development. The financial numbers are just cash.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.